TYRA News and Press, Tyra Biosciences Inc. From 02/01/24

Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia PR Newswire CARLSBAD, Calif. , Feb. 1, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on ...

2024-01-22 19:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-12 03:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-28 12:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference PR Newswire CARLSBAD, Calif. , Nov. 8, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation pre...

2023-11-08 10:15:36 ET More on Tyra Biosciences Tyra Biosciences: FDA ODD Designation Progresses TYRA-300 Seeking Alpha’s Quant Rating on Tyra Biosciences Historical earnings data for Tyra Biosciences Financial information for Tyra Biosciences ...

Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights PR Newswire - Enrollment and dose escalation ongoing in SURF301 Phase 1/2 oncology - - Presented additional preclinical data on TYRA-300 in achondroplasia at ASBMR and ASHG - - First patie...

Tyra Biosciences Inc. (TYRA) is expected to report $-0.35 for Q3 2023

Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings PR Newswire CARLSBAD, Calif. , Sept. 21, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company foc...

Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference PR Newswire CARLSBAD, Calif. , Sept. 12, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision...